The introduction of florbetapir (Amyvid) positron emission tomography biomarkers could dramatically change how we clinically evaluate young patients who present with nonamnestic cognitive complaints for possible Alzheimer disease (AD). Logopenic progressive aphasia (LPA) may be the most common example of this type of clinical problem. In most, but not all, cases, LPA is an early-onset AD variant presenting with language changes that can be difficult to distinguish from other progressive aphasias. We clinically evaluated 3 patients with LPA, in comparison with age-matched and severity-matched patients with typical amnestic AD, using florbetapir amyloid neuroimaging. The fluorodeoxyglucose-positron emission tomography scans of LPA patients revealed focal hypometabolism in the left temporoparietal areas, and the florbetapir scans were diffusely positive for the presence of amyloid deposition. The florbetapir scans did not differ in distribution between patients with LPA and those with typical amnestic AD. Clinical amyloid imaging, although lacking localizing value, is a major advance in the assessment of early-onset and nonamnestic patients for the presence of b-amyloid Alzheimer pathology.
A lzheimer disease (AD) in patients below the age of 65 years often presents with atypical, nonmemory presentations that may be difficult to recognize because of AD. 1 In the absence of a relatively determinative test or biomarker, these patients often remain undiagnosed in their earliest stages, when therapeutic and psychosocial intervention may be most helpful. This situation, however, may change with the recent clinical availability of amyloid neuroimaging.
Logopenic progressive aphasia (LPA), or the logopenic variant of primary progressive aphasia (PPA), is a language impairment, which is one of the known variant presentations of early-onset AD. 1 The criteria for LPA include the presence of both impaired single-word retrieval in spontaneous speech and naming and impaired repetition of sentences and phrases. 2 LPA also has at least 2 of the following: speech (phonological) errors; spared single-word comprehension; spared motor speech; and absence of frank agrammatism. 2 LPA can be difficult to distinguish from the nonfluent/agrammatic variant of PPA aphasia associated with frontotemporal degeneration pathology (FTLD). In fact, there is much overlap between the different clinical syndromes of PPA, and the clinical examination by itself may be insufficient or unreliable for predicting AD or FTLD pathology. 3 The clinical availability of amyloid neuroimaging with [ 18 F]florbetapir (Amyvid) may facilitate the recognition of LPA because of Alzheimer-related amyloid pathology. Florbetapir is the first FDA-approved radioactive diagnostic agent, used with positron emission tomography (PET) imaging, for visualizing fibrillar amyloid plaques in patients with possible AD. 4 A positive scan corresponds to b-amyloid deposition in the brain of people with AD, as well as in some people who are aging. 4 Among patients with early-onset cognitive difficulties, however, the presence of a positive florbetapir scan is a good indicator of Alzheimer pathology.
We present 3 patients with LPA, compared with 3 agematched patients with typical amnestic AD, who were evaluated using fluorodeoxyglucose (FDG) and florbetapir PET imaging. These patients illustrate that clinical florbetapir imaging can support the presence of amyloid pathology in cognitive variants of early-onset AD.
METHODS

Participants
This report included 3 patients who presented to a university clinic specializing in early-onset dementia and met the published criteria for LPA. 2 They were matched on approximate age, sex, and Mini-Mental State Examination scores, with additional 3 patients from the same clinic who met the criteria for AD. 5 As part of the clinical evaluation, these patients underwent florbetapir PET imaging. We obtained the images on a Siemens 953/31 PET scanner (voxel size 1.96Â 1.96Â3.38 mm; Siemens Medical Solutions, Hoffman Estates, IL). Eli Lilly/ AVID pharmaceuticals Inc. provided the [ 18 F]florbetapir tracer. We injected the patients with a 10 mCi dose and obtained 20-minute images, 50 to 70 minutes after dose injection. Trained neuroimagers (AmyvidTraining.com) interpreted the scans as positive or negative depending on the attenuation of the normal gray-white contrast differences.
Neurocognitive testing included the following 6 : Mini-Mental State Examination, digit span forward, "F" letter and "animal" category word-list generation, 20-item extended mini-Boston Naming Test, dysfluency scale (words/min, phrase length, effort, halting), sentence repetition, word and sentence comprehension, Consortium to Establish a Registry in AD (CERAD), delayed recall,
RESULTS
No differences were observed in age, age of onset, education, or most neurocognitive measures (Table 1) . Memory testing did not distinguish the LPA and AD patients in this small sample. The LPA patients, however, were more impaired on dysfluency and sentence repetition, and the AD patients were more impaired on constructions and visuoperceptual (Perceptual Assessment Battery) measures.
On FDG-PET imaging, the LPA patients had mild left posterior temporoparietal hypometabolism ( Fig. 1) , whereas the AD patients had bilateral parietal hypometabolism (except for patient D, whose FDG scan was normal). On florbetapir PET imaging, all 6 patients had 
DISCUSSION
This report illustrates the diagnostic value and practical application of amyloid neuroimaging with [ 18 F]florbetapir in early-onset AD variants. The LPA patients had unilateral posterior temporoparietal hypometabolism on FDG-PET and diffusely positive florbetapir scans for amyloid pathology, indistinguishable from those observed in patients with typical AD. Although lacking localizing value, the amyloid neuroimaging was able to confirm the suspicion of mild stages of early-onset AD in these patients.
LPA is usually a form of early-onset AD. 1 LPA appears to result from a deficit in the phonologic loop or short-term memory store for phonological memory traces because of asymmetric involvement of the left posterior temporoparietal cortex. 2, 3, 7 However, there is still controversy over whether the clinical examination is specific or is able to distinguish LPA, which primarily results from AD, compared with the other PPAs, which primarily result from FTLD. 3 Moreover, LPA may progress rapidly, losing its distinctiveness as it evolves to dementia. 8 For these reasons, the early recognition of LPA is important if ADrelated interventions are to be initiated early.
Amyloid imaging can define the preclinical and early stages of syndromes related to Alzheimer pathology. The most prominently studied amyloid imaging ligand is 11Clabeled PET tracer Pittsburgh compound B (PiB). This compound binds to fibrillar b-amyloid plaques on PET imaging and correlates with the presence of b-amyloid neuropathology. PiB has been a tremendous asset as a research tool, but its short half-life (about 20 min) requires an onsite cyclotron and is difficult to implement in most clinical settings. Compounds with longer half-lives, such as florbetapir, are more clinically useful. The FDA approved florbetapir in early 2012 for the clinical detection of amyloid deposition as an indicator of AD. 9 An Alzheimer's Association task force with the Society of Nuclear Medicine made the following recommendations for the use of clinical amyloid neuroimaging 9 : (1) patients with cognitive complaints and objectively confirmed impairment; (2) patients in whom diagnosis is uncertain (with AD being a possibility) after comprehensive evaluation by a dementia expert; and (3) the knowledge of amyloid-b status is expected to increase diagnostic certainty and alter management. All of these recommendations apply to the evaluation of patients with LPA.
Amyloid imaging may be particularly helpful in differentiating LPA from PPAs, not because of Alzheimer neuropathology, but does not have localizing value (Fig. 1) . Amyloid imaging shows significant discrimination between AD patients and normal controls; however, it does not help in localizing cognitive deficits and syndromes. 10 As in our patients, other reports have not found focal amyloid signal on PET corresponding to focal FDG-PET hypometabolism, which is usually asymmetric left temporoparietal hypometabolism in LPA. 10 Fibrillar b-amyloid deposition occurs early in AD, long before the symptoms occur; the clinical presence of LPA correlates with the presence of neurofibrillary tangles in the left temporoparietal region, rather than b-amyloid deposition. 7 In conclusion, clinical florbetapir neuroimaging can help define early-onset AD variants, such as LPA, because of Alzheimer pathology. This is a preliminary report, and there remain potential issues related with the reliability of florbetapir imaging and reading in the community. However, these patients illustrate how clinically-available amyloid imaging can be useful in the assessment of patients for AD. In future, more extensive research would help define the clinical role of florbetapir imaging.
